Battle Card: CGT Global Scales Cell Therapy Ops with New Advisor
CGT Global taps Dr. Jerome Ritz for board-level clout. Pitch your manufacturing automation and supply chain visibility now. Fuel your pipeline, hit quota fast.
Published on
Do not index
Do not index
🚀 Battle Card: CGT Global
Quick trigger:
👤 Decision Maker in the News
- Dr. Jerome Ritz, Board of Advisors Member · 🔗 LinkedIn
💡 Why It Matters
- This CGT Global sales trigger signals a push to scale GMP cell manufacturing and enhance clinical operations. → Source
🎯 Core Pain Point
- Scaling GMP-compliant cell and gene therapy manufacturing capacity
- Ensuring supply chain visibility and reliability across clinical sites
💰 What to Pitch
- Primary: Cell therapy manufacturing automation platform → Accelerate batch throughput by 30%
- Expansion: Supply chain visibility dashboard → Mitigate delays and forecast demand in real time
- Leverage this CGT Global sales trigger to tailor ROI in your outreach.
🗺️ Quick Context
- HQ: Folsom, CA
- Employees: ≈ 300
- Rev: ≈ $75 M
- Website: https://www.cgt.global
🤼 Competitive Intel
Which other vendors you’ll probably face to win CGT Global’s business.
- Thermo Fisher Scientific — GMP manufacturing & supply chain
- Unique edge: Global scale with end-to-end regulatory compliance
- Evaluated by VP Ops & Dir of Supply Chain
- Catalent — Cell & gene therapy manufacturing
- Unique edge: Integrated clinical-to-commercial services
- Evaluated by VP Ops & CMO
- WuXi AppTec — Cell & gene therapy outsourcing
- Unique edge: Flexible global capacity across multiple sites
- Evaluated by COO & VP Supply Chain
- Lonza — Contract development & manufacturing
- Unique edge: Broad technical platform with strong academic partnerships
- Evaluated by Dir. Manufacturing for process robustness
✅ Do-Now Checklist
Connect with Dr. Jerome Ritz on LinkedIn (link above)
Craft email & DM referencing this CGT Global sales trigger and your solution value
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Leverage the CGT Global sales trigger every day for pipeline growth.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑❑
OFFER_BRIEF = ❑cell therapy manufacturing automation platform❑
PROOF_METRIC = ❑accelerated batch throughput by 30%❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Jerome
COMPANY = CGT Global
DEPT = Ops & Supply Chain
SIZE = ≈ TBD
BOTTLENECK = scaling GMP-compliant cell and gene therapy manufacturing capacity
EVENT = Welcomes Dr. Jerome Ritz to Its Board of Advisors
DETAIL = his appointment to the Board of Advisors
PAIN = Ensuring supply chain visibility and reliability across clinical sites
SRC = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250814468290&div=41152219
SIM_CO = Thermo Fisher Scientific
WIN_METRIC = accelerated batch throughput by 30%
NEXT_SIZE = ≈ TBD
EMP_EST = ≈ 300
REV_EST = ≈ $75 M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈ TBD-person Ops & Supply Chain
Jerome—noticed your Ops & Supply Chain team is ≈ TBD.
That’s when scaling GMP-compliant cell and gene therapy manufacturing capacity slows growth.
We helped Thermo Fisher Scientific fix this with cell therapy manufacturing automation platform.
Result: accelerated batch throughput by 30%.
Quick call?
PS—next bottleneck hits ≈ TBD.
DM ≤45 words, TONE:
Saw your post about his appointment to the Board of Advisors — Ensuring supply chain visibility and reliability across clinical sites.
cell therapy manufacturing automation platform. accelerated batch throughput by 30%.
Quick chat?